drugset / Trial / NCT06244823

The FreMRI Study: Advanced MRI on Migraine Patients Treated With Fremanezumab

NCT06244823

NaSingle-groupOpen-labelTreatment

Summary

The goal of this open-label, single-blind, controlled-trial is to evaluate brain changes evaluated with diffusion Magnetic Resonance Imaging (MRI) and functional MRI in patients with high-frequency episodic migraine and chronic migraine that will be treated with Fremanezumab, 12 weeks after the treatment onset, compared with the baseline. Type of study: Phase IV clinical trial Participant population: high-frequency episodic migraine and chronic migraine. Participants will be treated with Fremanezumab.

Timeline

Start
2023-03-01
Primary completion
2024-10-01
Completion
2025-01-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fremanezumab Monoclonal antibody 225 mg Subcutaneous